These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

563 related articles for article (PubMed ID: 29710224)

  • 1. Hormone Replacement Therapy After Oophorectomy and Breast Cancer Risk Among BRCA1 Mutation Carriers.
    Kotsopoulos J; Gronwald J; Karlan BY; Huzarski T; Tung N; Moller P; Armel S; Lynch HT; Senter L; Eisen A; Singer CF; Foulkes WD; Jacobson MR; Sun P; Lubinski J; Narod SA;
    JAMA Oncol; 2018 Aug; 4(8):1059-1065. PubMed ID: 29710224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers.
    Metcalfe K; Lynch HT; Foulkes WD; Tung N; Kim-Sing C; Olopade OI; Eisen A; Rosen B; Snyder C; Gershman S; Sun P; Narod SA
    JAMA Oncol; 2015 Jun; 1(3):306-13. PubMed ID: 26181175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Breast cancer risk and hormone replacement therapy among BRCA carriers after risk-reducing salpingo-oophorectomy.
    Michaelson-Cohen R; Gabizon-Peretz S; Armon S; Srebnik-Moshe N; Mor P; Tomer A; Levy-Lahad E; Paluch-Shimon S
    Eur J Cancer; 2021 May; 148():95-102. PubMed ID: 33743487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hormone replacement therapy after menopause and risk of breast cancer in BRCA1 mutation carriers: a case-control study.
    Kotsopoulos J; Huzarski T; Gronwald J; Moller P; Lynch HT; Neuhausen SL; Senter L; Demsky R; Foulkes WD; Eng C; Karlan B; Tung N; Singer CF; Sun P; Lubinski J; Narod SA
    Breast Cancer Res Treat; 2016 Jan; 155(2):365-73. PubMed ID: 26780555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group.
    Rebbeck TR; Friebel T; Wagner T; Lynch HT; Garber JE; Daly MB; Isaacs C; Olopade OI; Neuhausen SL; van 't Veer L; Eeles R; Evans DG; Tomlinson G; Matloff E; Narod SA; Eisen A; Domchek S; Armstrong K; Weber BL;
    J Clin Oncol; 2005 Nov; 23(31):7804-10. PubMed ID: 16219936
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of total abdominal hysterectomy and hormone replacement therapy in BRCA1 and BRCA2 mutation carriers undergoing risk-reducing salpingo-oophorectomy.
    Gabriel CA; Tigges-Cardwell J; Stopfer J; Erlichman J; Nathanson K; Domchek SM
    Fam Cancer; 2009; 8(1):23-8. PubMed ID: 18758995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bilateral Oophorectomy and All-Cause Mortality in Women With BRCA1 and BRCA2 Sequence Variations.
    Kotsopoulos J; Gronwald J; Huzarski T; Møller P; Pal T; McCuaig JM; Singer CF; Karlan BY; Aeilts A; Eng C; Eisen A; Bordeleau L; Foulkes WD; Tung N; Couch FJ; Fruscio R; Neuhausen SL; Zakalik D; Cybulski C; Metcalfe K; Olopade OI; Sun P; Lubinski J; Narod SA;
    JAMA Oncol; 2024 Apr; 10(4):484-492. PubMed ID: 38421677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation.
    Finch A; Beiner M; Lubinski J; Lynch HT; Moller P; Rosen B; Murphy J; Ghadirian P; Friedman E; Foulkes WD; Kim-Sing C; Wagner T; Tung N; Couch F; Stoppa-Lyonnet D; Ainsworth P; Daly M; Pasini B; Gershoni-Baruch R; Eng C; Olopade OI; McLennan J; Karlan B; Weitzel J; Sun P; Narod SA;
    JAMA; 2006 Jul; 296(2):185-92. PubMed ID: 16835424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk-Reducing Bilateral Salpingo-Oophorectomy for BRCA Mutation Carriers and Hormonal Replacement Therapy: If It Should Rain, Better a Drizzle than a Storm.
    Gasparri ML; Taghavi K; Fiacco E; Zuber V; Di Micco R; Gazzetta G; Valentini A; Mueller MD; Papadia A; Gentilini OD
    Medicina (Kaunas); 2019 Jul; 55(8):. PubMed ID: 31362334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hormone replacement therapy after prophylactic risk-reducing salpingo-oophorectomy and breast cancer risk in BRCA1 and BRCA2 mutation carriers: A meta-analysis.
    Marchetti C; De Felice F; Boccia S; Sassu C; Di Donato V; Perniola G; Palaia I; Monti M; Muzii L; Tombolini V; Benedetti Panici P
    Crit Rev Oncol Hematol; 2018 Dec; 132():111-115. PubMed ID: 30447915
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hormone replacement therapy in BRCA mutation carriers and risk of ovarian, endometrial, and breast cancer: a systematic review.
    Huber D; Seitz S; Kast K; Emons G; Ortmann O
    J Cancer Res Clin Oncol; 2021 Jul; 147(7):2035-2045. PubMed ID: 33885953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prophylactic oophorectomy reduces breast cancer penetrance during prospective, long-term follow-up of BRCA1 mutation carriers.
    Kramer JL; Velazquez IA; Chen BE; Rosenberg PS; Struewing JP; Greene MH
    J Clin Oncol; 2005 Dec; 23(34):8629-35. PubMed ID: 16314625
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality.
    Domchek SM; Friebel TM; Singer CF; Evans DG; Lynch HT; Isaacs C; Garber JE; Neuhausen SL; Matloff E; Eeles R; Pichert G; Van t'veer L; Tung N; Weitzel JN; Couch FJ; Rubinstein WS; Ganz PA; Daly MB; Olopade OI; Tomlinson G; Schildkraut J; Blum JL; Rebbeck TR
    JAMA; 2010 Sep; 304(9):967-75. PubMed ID: 20810374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Role of Hormonal Replacement Therapy in BRCA Mutated Patients: Lights and Shadows.
    Loizzi V; Dellino M; Cerbone M; Arezzo F; Cazzato G; Damiani GR; Pinto V; Silvestris E; Kardhashi A; Cicinelli E; Cascardi E; Cormio G
    Int J Mol Sci; 2023 Jan; 24(1):. PubMed ID: 36614207
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
    Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
    Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short-term Impact of Hormone Replacement Therapy on Risk of Breast Cancer in BRCA Mutation Carriers: A Nationwide Study in South Korea.
    Kim HY; Park J; Moon SJ; Jeong S; Hong JH; Lee JK; Cho GJ; Cho HW
    Cancer Res Treat; 2024 Jan; 56(1):143-148. PubMed ID: 37591780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers.
    Rebbeck TR; Levin AM; Eisen A; Snyder C; Watson P; Cannon-Albright L; Isaacs C; Olopade O; Garber JE; Godwin AK; Daly MB; Narod SA; Neuhausen SL; Lynch HT; Weber BL
    J Natl Cancer Inst; 1999 Sep; 91(17):1475-9. PubMed ID: 10469748
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bilateral Oophorectomy and Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers.
    Kotsopoulos J; Huzarski T; Gronwald J; Singer CF; Moller P; Lynch HT; Armel S; Karlan B; Foulkes WD; Neuhausen SL; Senter L; Tung N; Weitzel JN; Eisen A; Metcalfe K; Eng C; Pal T; Evans G; Sun P; Lubinski J; Narod SA;
    J Natl Cancer Inst; 2017 Jan; 109(1):. PubMed ID: 27601060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hormone therapy after prophylactic risk-reducing bilateral salpingo-oophorectomy in women who have BRCA gene mutation.
    Guidozzi F
    Climacteric; 2016 Oct; 19(5):419-22. PubMed ID: 27426853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation.
    Finch AP; Lubinski J; Møller P; Singer CF; Karlan B; Senter L; Rosen B; Maehle L; Ghadirian P; Cybulski C; Huzarski T; Eisen A; Foulkes WD; Kim-Sing C; Ainsworth P; Tung N; Lynch HT; Neuhausen S; Metcalfe KA; Thompson I; Murphy J; Sun P; Narod SA
    J Clin Oncol; 2014 May; 32(15):1547-53. PubMed ID: 24567435
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.